Affimed (NASDAQ:AFMD) Sees Large Increase in Short Interest

Affimed (NASDAQ:AFMD) saw a large growth in short interest in March. As of March 31st, there was short interest totalling 196,400 shares, a growth of 14.5% from the March 15th total of 171,600 shares. Based on an average daily trading volume, of 98,300 shares, the days-to-cover ratio is currently 2.0 days. Approximately 1.5% of the company’s shares are sold short.

Affimed Trading Down 2.7 %

NASDAQ:AFMD opened at $5.75 on Friday. Affimed has a one year low of $2.23 and a one year high of $11.10. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.23 and a current ratio of 3.25. The firm has a market cap of $87.57 million, a P/E ratio of -0.68 and a beta of 2.05. The firm has a 50-day simple moving average of $5.56 and a 200-day simple moving average of $4.99.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. StockNews.com assumed coverage on shares of Affimed in a report on Tuesday, January 2nd. They set a “sell” rating for the company. Wells Fargo & Company decreased their price objective on shares of Affimed from $30.00 to $25.00 and set an “overweight” rating for the company in a report on Monday, April 1st. HC Wainwright lifted their price objective on shares of Affimed to $10.00 and gave the company a “buy” rating in a report on Monday, April 1st. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Affimed in a report on Monday, April 1st. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $45.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of AFMD. XTX Topco Ltd purchased a new position in shares of Affimed in the 1st quarter worth approximately $27,000. Schonfeld Strategic Advisors LLC purchased a new position in shares of Affimed in the 2nd quarter worth approximately $31,000. UBS Group AG grew its position in shares of Affimed by 42.2% in the 1st quarter. UBS Group AG now owns 47,073 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 13,979 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Affimed by 30.9% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 13,570 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 3,202 shares during the last quarter. Finally, Advisor Group Holdings Inc. grew its position in shares of Affimed by 258.3% in the 1st quarter. Advisor Group Holdings Inc. now owns 8,967 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 6,464 shares during the last quarter. Hedge funds and other institutional investors own 30.82% of the company’s stock.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.